Australia's most trusted
source of pharma news
Sunday, 05 October 2025
Posted 30 September 2025 AM
The TGA has cleared Takeda's ADHD medication Vyvanse against allegations of potential lack of effectiveness, quality and safety after bizarre claims took off on social media.
An investigation by the regulator found no issues of concern with the drug following a spike in reported adverse events, triggered by two tiny typographical errors on the packaging which sparked a social media frenzy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.